AnPac Bio Announces Filing of Annual Report on Form 20-F for 2020

Rhea-AI Summary

AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) has filed its annual report on Form 20-F for the fiscal year ending December 31, 2020, with the SEC as of April 30, 2021. The report includes audited consolidated financial statements and is accessible on the SEC's website and the company's investor relations page. AnPac Bio specializes in early cancer screening and detection, holding 142 patents as of March 31, 2021. The company's Cancer Differentiation Analysis technology can detect over 20 cancer types with high sensitivity and specificity.

Positive

• 142 patents issued as of March 31, 2021.
• Ranked third globally for early cancer screening technologies based on 41,700 clinical samples.
• Proven CDA technology detects risk for over 20 cancer types.

Negative

• None.

SAN JOSE, Calif., April 30, 2021 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC) (“AnPac Bio” or the “Company”), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, announced today that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2020 with the U.S. Securities and Exchange Commission (the “SEC”) on April 30, 2021.

The Company’s annual report on Form 20-F, which contains its audited consolidated financial statements, can be accessed on and downloaded from the SEC’s website at www.sec.gov as well as on the Company’s investor relations website at https://www.anpacbio.com.

About AnPac Bio

AnPac Bio is a biotechnology company focused on early cancer screening and detection, with 142 issued patents as of March 31, 2021. With two certified clinical laboratories in China and one CLIA and CAP accredited clinical laboratory and one CLIA registered clinical laboratory in the United States, AnPac Bio performs a suite of cancer screening and detection tests, including CDA (Cancer Differentiation Analysis), bio-chemical, immunological, and genomics tests. According to Frost & Sullivan, AnPac Bio ranked third worldwide among companies offering next-generation early cancer screening and detection technologies in terms of the number of clinical samples for cancer screening and detection, based on approximately 41,700 clinical samples as of December 2019. AnPac Bio’s CDA technology platform has been shown in retrospective validation studies to be able to detect the risk of over 20 different cancer types with high sensitivity and specificity.

For more information, please visit: https://www.Anpacbio.com.

For investor and media inquiries, please contact:

Company:
Phil Case, Marketing and Investor Relations
Phone: +1-267-810-6776 (US)
Email: phil_case@AnPacbio.com

Investor Relations:
Ascent Investor Relations LLC
Tina Xiao, President
Phone: +1-917-609-0333 (US)
Email: tina.xiao@ascent-ir.com

FAQ

What did AnPac Bio announce on April 30, 2021?

AnPac Bio announced the filing of its annual report on Form 20-F for the fiscal year ended December 31, 2020.

Where can I access AnPac Bio's annual report?

AnPac Bio's annual report can be accessed on the SEC's website and the company's investor relations website.

How many patents does AnPac Bio hold?

AnPac Bio holds 142 issued patents as of March 31, 2021.

What technology does AnPac Bio use for cancer detection?

AnPac Bio uses its Cancer Differentiation Analysis (CDA) technology for cancer detection.

How effective is AnPac Bio's CDA technology?

CDA technology has shown the ability to detect the risk of over 20 different cancer types with high sensitivity and specificity.